Efficacy of Sofosbuvir and Ledipasvir in Comparison to Sofosbuvir and Daclatasvir in Management of Egyptian Chronic Hepatitis C Patients
Afro-Egypt. j. infect. enem. dis
; 10(2): 163-173, 2022. tables, figures
Article
in English
| AIM
| ID: biblio-1426649
Responsible library:
CG1.1
ABSTRACT
In Egypt, the prevalence of hepatitis C virus (HCV) antibodies is the highest worldwide by 7.6%. Applying efficient treatment protocol on large scale could decrease HCV prevalence as well as disease burden.The aim of this study is to compare the efficacy of Sofosbuvir plus ledipasvir versus Sofosbuvir plus daclatasvir in management of chronic hepatitis C Egyptian patients with either easy to treat (naive patients with Child score A5)or difficult to treat (interferon experienced).
Full text:
Available
Index:
AIM (Africa)
Main subject:
Treatment Outcome
/
Hepatitis C, Chronic
Type of study:
Practice guideline
/
Observational study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Afro-Egypt. j. infect. enem. dis
Year:
2022
Type:
Article
Institution/Affiliation country:
2 Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls, AL-Azhar/EG
/
Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls/EG
/
Tropical Medicine Department , National Hepatology and Tropical Medicine R R Research Institute/EG
Similar
MEDLINE
...
LILACS
LIS